## Why option 1 is correct NYHA Class IV heart failure (marked **D**) represents advanced heart failure with symptoms present at rest and severe limitation with any activity. The clinical anchor mandates STABILIZATION as the immediate priority in acute decompensation: (1) IV loop diuretics (furosemide 40–80 mg initially, higher than outpatient doses) to reduce pulmonary congestion; (2) supplemental oxygen to maintain SpO2 ≥ 90%; and (3) NIPPV for severe pulmonary edema to improve oxygenation and reduce work of breathing. This patient's SpO2 of 78% at rest, bilateral pulmonary edema, and respiratory distress mandate urgent stabilization before any other intervention. Harrison 21e Ch 252 and ACC/AHA HF Guidelines 2022 emphasize that acute decompensated Class IV HF requires hemodynamic stabilization first. ## Why each distractor is wrong - **Option 2**: While GDMT (metoprolol succinate, spironolactone, dapagliflozin) is essential for long-term management of HFrEF, oral medications cannot be initiated as first-line therapy in acute decompensation with respiratory distress, hypotension, and hypoxemia. These agents must be introduced after hemodynamic stabilization and are typically started or optimized during hospital stay or after discharge. - **Option 3**: Cardiac catheterization and IABP insertion are reserved for cardiogenic shock with inadequate perfusion or acute mechanical complications (papillary muscle rupture, VSD). This patient, while hypotensive, does not meet criteria for cardiogenic shock requiring mechanical support as an immediate intervention; stabilization with diuretics and vasodilators is the first step. - **Option 4**: Diuretic-free management is contraindicated in acute pulmonary edema with hypoxemia. Diuretics are the cornerstone of acute decompensated HF management to relieve congestion. Vasodilators alone without diuretics and oxygen will not adequately address the life-threatening pulmonary edema and hypoxemia. **High-Yield:** NYHA Class IV HF acute decompensation = STABILIZE FIRST (IV diuretics, O2, NIPPV) → then GDMT (ARNI/ACE-I + β-blocker + MRA + SGLT2i) → then DEVICE THERAPY (ICD/CRT) if indicated. [cite: Harrison 21e Ch 252; ACC/AHA Heart Failure Guidelines 2022]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.